Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma

The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia

ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX", "Dogwood" or "the Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced FDA acceptance of an Investigational New Drug ("IND") application for its development candidate SP16, administered intravenously ("IV"), for the treatment of chemotherapy-induced pain and peripheral neuropathy ("CIPPN").

SP16 is administered via IV infusion with two hypothesized actions: anti-inflammatory actions via reduction of IL-6, IL-8, IL-1β and TNF-alpha, and tissue repair via increases in pAKT and pERK that regulate and promote fundamental processes like growth, proliferation, and survival. The Company and its partner Serpin Pharma anticipate patient enrollment in the SP16 Phase 1b trial to begin in the middle of 2026. Serpin Pharma has been awarded a $2.5 million grant from the National Cancer Institute ("NCI"), which will fully fund the forthcoming SP16 Phase 1b CIPPN clinical trial.